home / stock / hepa / hepa news


HEPA News and Press, Hepion Pharmaceuticals Inc. From 07/07/20

Stock Information

Company Name: Hepion Pharmaceuticals Inc.
Stock Symbol: HEPA
Market: NASDAQ
Website: hepionpharma.com

Menu

HEPA HEPA Quote HEPA Short HEPA News HEPA Articles HEPA Message Board
Get HEPA Alerts

News, Short Squeeze, Breakout and More Instantly...

HEPA - NVAX, MFGP, RUN and TOPS among midday movers

Gainers:  Corvus Pharmaceuticals (NASDAQ: CRVS ) +108% . More news on: Corvus Pharmaceuticals, Inc., Annovis Bio, Inc., Hepion Pharmaceuticals, Inc., Stocks on the move, , Read more ...

HEPA - NVAX, LVGO among premarket gainers

Corvus Pharmaceuticals (NASDAQ: CRVS ) +103%  on launch immunotherapy study for COVID-19. More news on: Corvus Pharmaceuticals, Inc., Annovis Bio, Inc., Novavax, Inc., Stocks on the move, , Read more ...

HEPA - Hepion Pharma's lead candidate shows encouraging action in COVID-19 models

Nano cap Hepion Pharmaceuticals (NASDAQ: HEPA ) announces positive results on lead drug CRV431 in two preclinical research models related to COVID-19. More news on: Hepion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

HEPA - Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431

- Positive CRV431 Data in Models of Acute Pulmonary Injury and SARS-CoV-2 Viral Replication - CRV431 attenuated lung inflammation and damage similar to or better than dexamethasone, including reductions in neutrophils and IL-6 CRV431 decreased SARS-CoV-2 replication and production...

HEPA - Hepion Pharmaceuticals: CRV431 Continues To Progress In Early Phase NASH Clinical Trials

Hepion Pharmaceuticals' ( HEPA ) drug, CRV431, has previously been studied in humans in Phase 1 single ascending dose clinical trial for Hepatitis B, an indication that management has deemphasized in favor of the larger NASH opportunity. In that study, the drug was found to be safe and well to...

HEPA - Hepion Pharma advances lead candidate in early-stage study

Nano cap Hepion Pharmaceuticals (NASDAQ: HEPA ) has advanced to the final dose level in a multiple oral ascending-dose Phase 1 clinical trial evaluating lead candidate CRV431 in healthy volunteers. More news on: Hepion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ...

HEPA - MU, SPG among premarket gainers

Blink Charging (NASDAQ: BLNK ) +56%  as momentum stays red-hot. More news on: Blink Charging Co., Polar Power, Inc., Broadway Financial Corporation, Stocks on the move, , Read more ...

HEPA - Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

EDISON, NJ / ACCESSWIRE / June 29, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the advancement to the f...

HEPA - IBN, EDIT among premarket losers

Marathon Patent Group (NASDAQ: MARA ) -14% . More news on: Marathon Patent Group, Inc., Fuwei Films (Holdings) Co., Ltd., Urban One, Inc., Stocks on the move, , Read more ...

HEPA - INO, HEPA, HTZ and SINT among midday movers

Gainers:  Lilis Energy (NYSEMKT: LLEX ) +93% . More news on: Lilis Energy, Inc., Fuwei Films (Holdings) Co., Ltd., China Rapid Finance Limited, Stocks on the move, , Read more ...

Previous 10 Next 10